Today: 21 May 2026
Marvell stock ticks higher after hours as CES CEO chat and Celestial AI deal stay in focus
31 December 2025
2 mins read

Marvell stock ticks higher after hours as CES CEO chat and Celestial AI deal stay in focus

NEW YORK, December 30, 2025, 18:45 ET — After-hours

  • Marvell shares were up about 1.1% at $86.76 in after-hours trading.
  • The S&P 500 and Nasdaq ended slightly lower after Fed minutes, with chip ETFs down modestly.
  • Investors are watching the Jan. 6 CES fireside chat with CEO Matt Murphy and the closing timetable for the Celestial AI acquisition.

Marvell Technology, Inc. shares were up about 1.1% at $86.76 in after-hours trading on Tuesday. The stock traded between $85.58 and $88.07 during the session. About 9.6 million shares changed hands.

The move came as Wall Street finished slightly lower in choppy, holiday-thin trade after the Federal Reserve released minutes from its December meeting. The S&P 500 slipped 0.14% and the Nasdaq fell 0.23%.

That matters for Marvell because shifts in rate expectations can swing valuations across AI-linked semiconductors, where investors pay up for growth that arrives later. Marvell also has a near-term readout on strategy when Chief Executive Matt Murphy speaks at a JP Morgan CES fireside chat on Jan. 6, its investor-relations calendar shows.

Marvell has been watched since Dec. 2, when the Santa Clara, California-based company said it would buy photonics startup Celestial AI for about $3.25 billion and forecast roughly $10 billion in revenue for its next fiscal year. Marvell and rival Broadcom help cloud companies design custom data-center chips, and the company said data-center revenue was expected to rise about 25% while custom-chip revenue would grow about 20%. It also issued a warrant to Amazon tied to photonic product purchases through 2030 that could allow Amazon to buy up to about $90 million of Marvell stock at an exercise price around $87.

A regulatory filing said the upfront consideration includes about $1 billion in cash and about 27.2 million Marvell shares, with up to an additional 27.2 million shares tied to revenue milestones. Marvell expects the transaction to close in the first quarter of calendar 2026, subject to regulatory approvals and other conditions.

The acquisition targets optical interconnects — connections that use light rather than electrical signals — as chipmakers look to move more data with less power inside AI data centers. In the deal announcement, Amazon Web Services Vice President Dave Brown said “we believe optical interconnects will play an important role in the future of AI infrastructure”. Marvell Technology, Inc.

Chip stocks were mixed on Tuesday. The iShares Semiconductor ETF (SOXX) slipped about 0.1% and VanEck Semiconductor ETF (SMH) fell about 0.3%, while Nvidia was down about 0.3% and Broadcom edged up about 0.2%.

Marvell’s small after-hours gain left it outperforming the broader chip ETFs, putting attention back on company-specific catalysts rather than sector beta. For investors, the question is whether optical links and custom silicon can expand fast enough to justify premium multiples in a rate-sensitive market.

The Jan. 6 appearance is likely to sharpen that debate. Traders will listen for any updated timeline on customer adoption of optical connectivity and any signal that spending is broadening beyond headline AI accelerators into networking and memory-heavy architectures.

In the near term, thin year-end liquidity can exaggerate moves in mid-cap semiconductors. A decisive push above the upper-$80s would test whether buyers are willing to chase the stock into January after a muted close for the Nasdaq.

Marvell’s late bid kept the stock on a firmer footing heading into the final trading day of the year. The next session will show whether the move holds once portfolio rebalancing and macro headlines return to the fore.

Stock Market Today

  • Analysts Boost Broadcom Price Targets Despite Stock Dip
    May 20, 2026, 11:22 PM EDT. Broadcom (AVGO) shares fell 6.5% to $411.07 on May 19, retreating from a record high of $439.79 on May 14. Despite this drop, several major analysts raised their price targets. Wells Fargo lifted its target to $545 from $430, TD Cowen to $500 from $405, and UBS to $490 from $475, all maintaining buy ratings. Evercore ISI's Mark Lipacis, a top-ranked analyst, raised his target to $582, citing growing demand for Broadcom's custom AI chips amid shifts in AI workloads. Risks remain from semiconductor market volatility and geopolitical tensions impacting chip deals. Broadcom's strategic moves, including its VMware acquisition and partnerships with Google and Meta for AI-focused chips, position it well in enterprise infrastructure and AI growth.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Goldman Sachs stock slips after Fed minutes — here’s what traders are watching next
Previous Story

Goldman Sachs stock slips after Fed minutes — here’s what traders are watching next

Newmont stock today: NEM ends higher as gold rebounds after sharp year-end swings
Next Story

Newmont stock today: NEM ends higher as gold rebounds after sharp year-end swings

Go toTop